Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

WMIC: Looking ahead to 2015

The 2014 World Molecular Imaging Congress (WMIC) put a spotlight on the basic science and translation of molecular imaging at the World Trade Center in Seoul, South Korea, from Sept. 17-20. Molecular Imaging caught up with three central figures of the 2015 WMIC to find out more about emerging trends in molecular imaging and ways in which the WMIS operates to aid translation of preclinical research to first-in-human trials.

Anti-tau Alzheimer’s therapeutic pushes forward in phase III clinical trials

TauRx Therapeutics announced today that enough subjects have been enrolled in the second of two phase III clinical trials to continue validating a tau aggregation inhibitor called LMTX for the treatment of mild Alzheimer's disease.

Thumbnail

Motion correction PET program bankrolled by UM, Brain Biosciences

The University of Maryland announced this month that 18 projects with a value of $4.7 million have been approved through the Maryland Industrial Partnership (MIPS) program, which is fostered by the Maryland Technology Enterprise Institute and A. James Clark School of Engineering. Projects include the development of cancer therapeutics and motion correction software for brain PET systems.

Thumbnail

WMIC 2014: Angiogenesis, nanotheranostics and stem cell imaging

This year’s World Molecular Imaging Congress (WMIC), the Annual Meeting of the World Molecular Imaging Society (WMIS), brought the most cutting edge research and technology in preclinical research and molecular imaging technology to the World Trade Center in Seoul, Korea, from Sept. 17-20.

Mediso reaches another milestone with 150th installation of preclinical integrated multimodality imaging system

Mediso Medical Equipment Developing and Service Ltd. is proud to announce the hundred and fiftieth installation of Mediso manufactured, integrated preclinical imaging systems, at the prestigious Edinburgh University.

Lymphoseek gets FDA orphan drug designation for head and neck cancers

Navidea, based in Dublin, Ohio, announced yesterday that the radiopharmaceutical company has received orphan drug designation for the small molecular radiotracer technetium-99m tilmanocept (Lymphoseek) specifically for sentinel lymph node mapping in cancer cases of the head and neck.

Thumbnail

FDG-PET parameters predict survival in non-small cell lung cancer

Quantitative PET metrics including metabolic tumor volume using F-18 FDG can project heath outcomes after chemoradiotherapy for patients with non-small cell lung cancer (NSCLC), according to a study presented Wednesday during the 2014 Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) held Sept. 14-17 at the Moscone Center in San Francisco.

Thumbnail

ASTRO 2014: Precise radiotherapy saves more sexual function for prostate cancer patients

External beam radiotherapy (EBRT) was compared with a combination therapy of EBRT and brachytherapy to see which provided long-term sexual health for patients with prostate cancer. Results indicated that both treatment plans led to a high level of sexual function due to isolated radiation, according to a study presented during the 2014 annual meeting of the American Society for Radiation Oncology (ASTRO) being held Sept. 14-17 at the Moscone Center in San Francisco.